IP Library Granted Patent US 8,568,424
Granted Patent B2
US 8,568,424 · App. 13/341,136 · Granted Oct 29, 2013

Hysteroscopic tissue removal system with improved fluid management and/or monitoring capabilities

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,568,424
App. No.
13/341,136
Granted
Oct 29, 2013
Kind
B2
Abstract

A hysteroscopic tissue removal system having improved fluid management and/or monitoring capabilities. According to one embodiment, the system includes a hysteroscope and a tissue removal device, the tissue removal device being selectively operable and being removably mounted in an operating channel of the hysteroscope. The system also includes a fluid source and a fluid pump, the fluid pump being coupled to the fluid source and to a fluid input channel of the hysteroscope so as to pump fluid from the fluid source to the fluid input channel, the fluid pump being selectively operable. The system further includes a selectively operable switch, coupled to both the tissue removal device and the fluid pump, for actuating both the tissue removal device and the pump. If desired, a delay mechanism may be interposed between the switch and the tissue removal device to delay operation of the tissue removal device relative to the pump.

Claims (32)

1. A processor-controlled tissue removal method, comprising:

introducing an initial quantity of fluid into a body cavity in order to distend the body cavity;

receiving a user-initiated signal to activate a tissue removal device having a distal working end disposed in the body cavity;

in response to the received activation signal, and prior to activation of the tissue removal device, commencing introduction of an additional quantity of fluid into the body cavity; and

activating the tissue removal device in order to remove tissue from the body cavity, wherein the tissue removal device is not activated until either (i) a predetermined time period has elapsed after commencing introduction of the additional quantity of fluid into the body cavity, or (ii) a predetermined elevated fluid pressure is reached within the body cavity due to the commenced introduction of the additional quantity of fluid.

2. The tissue removal method of claim 1 , wherein the tissue removal device is activated after a predetermined time period has elapsed after commencing the introduction of the additional quantity of fluid into the body cavity.

3. The tissue removal method of claim 1 , wherein the tissue removal device is activated after a predetermined elevated fluid pressure within the body cavity is reached due to the introduction of the additional quantity of fluid.

4. The tissue removal method of claim 1 , wherein the body cavity is a uterus, and the tissue removed from the body cavity is uterine fibroid tissue.

5. A processor-controlled method for removing tissue from a body cavity using a tissue removal system, the tissue removal system comprising an introducer and a tissue removal device having a distal working end disposed in the body cavity, the method comprising:

introducing fluid into the body cavity through the introducer until a desired fluid pressure level is reached in the body cavity;

receiving, through a user activation switch, a signal to activate the tissue removal device;

in response to the received activation signal, and prior to activation of the tissue removal device, activating a fluid pump to thereby introduce additional fluid into the body cavity through the introducer; and

activating the tissue removal device in order to remove the tissue from the body cavity,

wherein, in order to maintain the body cavity at least at the desired fluid pressure level, the additional fluid is introduced into the body cavity for a predetermined period before activating the tissue removal device, and

wherein the predetermined period is based upon at least one of a time period threshold and a fluid pressure threshold.

6. The method of claim 5 , further comprising, before activating the tissue removal device,

analyzing the time period threshold and the fluid pressure threshold; and

determining that one or both of the time period threshold and the pressure threshold has been satisfied.

7. The method of claim 5 , wherein the predetermined period is based upon the time period threshold, such that the tissue removal device is not activated until additional fluid has been introduced into the body cavity for a predetermined amount of time.

8. The method of claim 5 , wherein the predetermined period is based upon the fluid pressure threshold, such that the tissue removal device is not activated until a predetermined elevated fluid pressure level is reached in the body cavity due to the introduction of the additional fluid.

9. The method of claim 5 , wherein the body cavity is a uterus, and the tissue removed from the body cavity is uterine fibroid material.

10. A processor-controlled method for removing fibroid tissue from a wall of a uterine cavity using a tissue removal system, the tissue removal system comprising an introducer having a working end in fluid communication with the uterine cavity, and a tissue removal device extending through the introducer and having a working distal end located in the uterine cavity, the method comprising:

introducing fluid into the uterine cavity through the introducer to thereby distend the uterine cavity;

receiving, through a user activation switch, a signal to activate the tissue removal device;

in response to the received activation signal, and prior to activation of the tissue removal device, activating a fluid pump to thereby commence introduction of additional fluid into the uterine cavity through the introducer; and

activating the tissue removal device in order to remove the tissue from the uterine cavity,

wherein the tissue removal device is not activated until at least one of

(i) a predetermined time period has elapsed after activating the fluid pump in response to the received activation signal, or

(ii) a predetermined elevated fluid pressure is reached within the uterus cavity due to the commenced introduction of the additional quantity of fluid.

11. The fibroid tissue removal method of claim 10 , wherein the tissue removal device is activated after a predetermined time period has elapsed following activation of the fluid pump in response to the received activation signal.

12. The tissue removal method of claim 10 , wherein the tissue removal device is activated after a predetermined elevated fluid pressure is reached in the uterine cavity due to the introduction of the additional quantity of fluid.

13. The tissue removal method of claim 10 , wherein after activating the tissue removal device, fluid is evacuated from the uterine cavity through the tissue removal device.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2012
From: ADAMS, RONALD DAVID; SHUGRUE, NICOLE MARIE
To: HOLOGIC, INC.
Reel/Frame 027746/0004 →